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We measured early 2016/17 season influenza vac-
cine effectiveness (IVE) against influenza A(H3N2) in 
Europe using multicentre case control studies at pri-
mary care and hospital levels. IVE at primary care level 
was 44.1%, 46.9% and 23.4% among 0–14, 15–64 
and ≥ 65 year-olds, and 25.7% in the influenza vacci-
nation target group. At hospital level, IVE was 2.5%, 
7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. 
As in previous seasons, we observed suboptimal IVE 
against influenza A(H3N2).
The 2016/17 influenza season in Europe is marked 
by the predominant circulation of influenza A(H3N2) 
viruses [1], with significant pressure on hospitals, 
mostly due to patients aged 65 years and older devel-
oping severe disease [1]. Many European countries 
have reported excess all-cause mortality [2]. Initial 
estimates based on Swedish and Finnish electronic 
databases suggest low influenza vaccine effectiveness 
(IVE) among older adults [3,4]. We measured early IVE 
at primary care and hospital levels against laboratory-
confirmed influenza A(H3N2) in Europe.
Primary care and hospital-based 
multicentre case control studies in Europe 
to measure influenza vaccine effectiveness
We conducted separate multicentre primary care 
and hospital-based case–control studies and analy-
ses using the test-negative design (TND). We have 
described the methods in detail previously [5-7].
In the primary care study, comprising 893 practition-
ers (including general practitioners and paediatricians) 
in 12 countries, we included a systematic sample of all 
community-dwelling patients presenting to their prac-
titioner with influenza-like illness (ILI), as defined by 
the European Union ILI case definition (sudden onset 
of symptoms and at least one of the following systemic 
symptoms: fever or feverishness, malaise, headache, 
myalgia, and at least one of the following respiratory 
symptoms: cough, sore throat, shortness of breath). 
In the hospital study, comprising 27 hospitals from 11 
countries, we included community-dwelling patients 
aged 65 years and older admitted to hospital for influ-
enza-related clinical conditions with symptoms com-
patible with severe acute respiratory infection (SARI). 
Each study site adapted a generic protocol to their 
local setting [8,9].
At each study site, the study period commenced more 
than 14 days after the start of the vaccination campaign 
and lasted from the week of the first influenza case to 
the date of sending data for the interim analysis at the 
end of January 2017.
A case of confirmed influenza was an ILI (primary 
care) or SARI (hospital) patient who was swabbed and 
tested positive for influenza A(H3N2) virus using real-
time RT-PCR. Controls were ILI (primary care) or SARI 
(hospital) patients who tested negative for any influ-
enza virus using RT-PCR.
We excluded patients with contraindications for influ-
enza vaccination, SARI patients discharged from a pre-
vious hospital stay within 48 hours of symptom onset 
(hospital), those with a previous laboratory-confirmed 
influenza in the season, those refusing to participate 
or unable to consent, those who had received antiviral 
drugs before swabbing (primary care), those swabbed 
more than 7 days after symptom onset, patients with 
missing laboratory results and any patients positive to 
any influenza virus other than influenza A(H3N2). 
Practitioners and hospital teams collected clinical and 
epidemiological information including date of symp-
tom onset and date of swabbing, 2016/17 seasonal 
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Table 1a
Influenza A(H3N2) cases and controls included in the 2016/17 season influenza vaccine effectiveness analysis, I-MOVE/I-
MOVE+ multicentre case control studies (primary care (n = 5,023) and hospital (n = 635) levels) Europe, influenza season 
2016/17 
Variables
Primary care level Hospital level
Number of A(H3N2) 
n = 2,250
Number of controls 
n = 2,773
Number of A(H3N2) 
n = 267
Number of controls 
n = 368
n Total % n Total % n Total % n Total %
Median age (years) 29 28 79 80
Age groups (years) 
0–4 276 2,242 12.3 723 2,766 26.1 NA NA
5–14 508 2,242 22.7 336 2,766 12.1 NA NA
15–64 1,177 2,242 52.5 1,438 2,766 52.0 NA NA
65–79 234 2,242 10.4 214 2,766 7.7 138 267 51.7 185 368 50.3
≥ 80 47 2,242 2.1 55 2,766 2.0 129 267 48.3 183 368 49.7
Missing 8 7 0 0
Sex 
Female 1,126 2,237 50.3 1,407 2,758 51.0 141 267 52.8 190 368 51.6
Missing 13 15 0 0
Chronic conditions
At least one chronic condition 451 2,237 20.2 542 2,743 19.8 237 255 92.9 321 344 93.3
Missing 13 30 12 24
At least one hospitalisation in the 
previous 12 months for chronic conditions 26 2,196 1.2 57 2,686 2.1 66 247 26.7 146 334 43.7
Missing 54 87 20 34
Target group for vaccination 
Belongs to a target group for vaccination 616 2,241 27.5 706 2,755 25.6 267 267 100.0 368 368 100.0
Missing 9 18 0 0
Swab delay 
Swabbed within 3 days of symptom onset 2,024 2,250 90.0 2,291 2,773 82.6 154 267 57.7 212 368 57.6
Vaccination status 
Seasonal flu vaccination 16–17 231 2,250 10.3 301 2,773 10.9 108 267 40.4 191 368 51.9
Seasonal flu vaccination 15–16 223 2,196 10.2 316 2,665 11.9 117 252 46.4 199 362 55.0
Missing 54 108 15 6
Previous and current season influenza vaccination 
Not vaccinated in any season 1,929 2,196 87.8 2,284 2,665 85.7 128 252 50.8 147 362 40.6
Current season vaccination only 44 2,196 2.0 65 2,665 2.4 7 252 2.8 16 362 4.4
Previous season vaccination only 43 2,196 2.0 95 2,665 3.6 20 252 7.9 28 362 7.7
Current and previous season vaccination 180 2,196 8.2 221 2,665 8.3 97 252 38.5 171 362 47.2
Missing 54 108 15 6
Type of vaccine 
Not vaccinated 2019 2,215 91.2 2,472 2,725 90.7 159 261 60.9 177 359 49.3
Inactivated subunit egg 97 2,215 4.4 108 2,725 4.0 65 261 24.9 101 359 28.1
Inactivated split virion egg 71 2,215 3.2 118 2,725 4.3 32 261 12.3 74 359 20.6
Adjuvanted 18 2,215 0.8 21 2,725 0.8 5 261 1.9 7 359 1.9
Quadrivalent vaccine 10 2,215 0.5 6 2,725 0.2 0 261 0.0 0 359 0.0
Missing vaccine type 35 48 6 9
Month of onset 
October 2016 4 2,250 0.2 84 2,773 3.0 0 267 0.0 0 368 0.0
November 2016 154 2,250 6.8 759 2,773 27.4 3 267 1.1 6 368 1.6
December 2016 1,199 2,250 53.3 1,194 2,773 43.1 174 267 65.2 236 368 64.1
January 2017 893 2,250 39.7 736 2,773 26.5 90 267 33.7 126 368 34.2
NA: Not applicable.
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vaccination status, date of vaccination and vaccine 
product administered, 2015/16 seasonal vaccina-
tion status, sex, age, presence of chronic conditions, 
whether the patient belonged to a target group for 
influenza vaccination (primary care) and number of 
hospitalisations for chronic conditions in the past 12 
months.
We defined individuals as vaccinated if they had 
received at least one dose of the 2016/17 influenza vac-
cine at least 15 days before ILI/SARI symptom onset. 
We excluded individuals vaccinated less than 15 days 
before symptom onset and individuals with unknown 
vaccination date.
At primary care level, nine study sites (France, 
Germany, Hungary, Ireland, the Netherlands, Portugal, 
Romania, Spain and Sweden) participated in a sub-
study using an in-depth laboratory protocol, and ran-
domly selected positive influenza A(H3N2) specimens 
for genetic sequencing.
We pooled individual patient data in each study and 
computed the pooled IVE as ((1−OR of vaccination 
between cases and controls) × 100) using logistic 
regression with study site as a fixed effect. We con-
ducted a complete case analysis excluding patients 
with missing values for any of the variables in the 
model. All IVE estimates were adjusted for study 
site, calendar time of onset and age (where sample 
size allowed). Further potential confounding factors 
included sex, underlying chronic conditions and hospi-
talisations in the past year.
We stratified IVE by age group. We measured IVE 
among the target groups for influenza vaccination at 
primary care level, defined as older adults (aged over 
54, 59 or 64 years depending on study site), individu-
als with chronic conditions and other groups for whom 
the vaccine was recommended in a given country (e.g. 
pregnant women, healthcare workers and other profes-
sional groups, depending on the study site). 
Influenza vaccine effectiveness in primary 
care
In the primary care analysis, we included 2,250 cases 
of influenza A(H3N2) and 2,773 negative controls.
The 2016/17 seasonal influenza vaccine coverage was 
10.3% among influenza A(H3N2) cases and 10.9% 
among controls. Compared with cases, a greater pro-
portion of controls belonged to the age group of 
0–4-year-olds (26.1% vs 12.3%) and a lower proportion 
belonged to the age group of 5–14-year-olds (12.1% vs 
22.7%) (Table 1).
Nine study sites sequenced 204 randomly selected 
specimens out of 1,817 (11.2%) (Table 2). Of these, 156 
(76.5%) belonged to the 3C.2a1 clade A/Bolzano/7/2016, 
46 (22.5%) to A/Hong Kong/4801/2014 (3C.2a) and two 
(1.0%) to A/Switzerland/9715293/2013 (3C.3a).
Variables
Primary care level Hospital level
Number of A(H3N2) 
n = 2,250
Number of controls 
n = 2,773
Number of A(H3N2) 
n = 267
Number of controls 
n = 368
n Total % n Total % n Total % n Total %
Study sites 
Croatia 13 2,250 0.6 13 2,773 0.5 NA NA
Finland NA NA 14 267 5.2 17 368 4.6
France 584 2,250 26.0 609 2,773 22.0 35 267 13.1 116 368 31.5
Germany 28 2,250 12.8 873 2,773 31.5 NA NA
Hungary 39 2,250 1.7 84 2,773 3.0 NA NA
Ireland 135 2,250 6.0 113 2,773 4.1 NA NA
Italy 411 2,250 18.3 367 2,773 13.2 37 267 13.9 58) 368 15.8
Lithuania NA NA 30 267 11.2 18 368 4.9
Navarra NA NA 20 267 7.5 34 368 9.2
The Netherlands 47 2,250 2.1 142 2,773 5.1 6 267 2.2 19 368 5.2
Poland 9 2,250 0.4 33 2,773 1.2 NA NA
Portugal 156 2,250 6.9 80 2,773 2.9 36 267 13.5 14 368 3.8
Romania 27 2,250 1.2 9 2,773 0.3 60 267 22.5 37 368 10.1
Spain 474 2,250 21.1 303 2,773 10.9 29 267 10.9 55 368 14.9
Sweden 66 2,250 2.9 147 2,773 5.3 NA NA
NA: Not applicable.
Table 1b
Influenza A(H3N2) cases and controls included in the 2016/17 season influenza vaccine effectiveness analysis, I-MOVE/I-
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n % n % n % n % n % n % n % n % n % n %
A/HongKong/4801/2014 (3C.2a) 10 6 3 0 8 8 4 3 4 46
N121K + S144K 3 30 6 100 3 100 0 1 12 8 100 4 100 3 100 3 75 31 67
A/Bolzano/7/2016 (3C.2a1) 33 19 3 5 20 23 8 36 9 156
N171K + N121K + I140M 10 30 0 0 0 7 35 2 9 4 50 8 22 3 33 34 22
N171K + N121K + T135K 2 6 0 2 67 0 3 15 0 0 1 3 3 33 11 7
N171K + N121K + K92R + H311Q 8 24 0 1 33 1 20 4 20 4 17 0 10 28 0 28 18
N171K + R142G 7 21 3 16 0 3 60 3 15 17 74 0 1 3 1 11 35 22
A/Switzerland/9715293/2013 
(3C.3a) 0 0 0 2 0 0 0 0 0 2
Total sequenced/total A(H3N2) 43 15 25 4 6 15 7 5 28 60 31 20 12 44 39 8 13 20 204 11
Table 3
Pooled adjusted seasonal vaccine effectiveness against laboratory-confirmed influenza A(H3N2) by age group and target 
group for vaccination, I-MOVE/I-MOVE+ multicentre case control studies (primary care (n = 4,937) and hospital (n = 635)), 
influenza season 2016/17 
Analyses Adjustment / stratification
Cases Controls Adjusted 
VE 95% CIAll Vaccinated % All Vaccinated %
Primary care
All ages 
Adjusted by study site only 2,216 229 10 2,721 297 11 10.9 −8.3 to 26.6
Adjusted by calendar time and 
study site 2,216 229 10 2,721 297 11 27.9 11.9 to 41.1
Adjusted by calendar time, age 
and study site 2,216 229 10 2,721 297 11 38.4   22.2 to 51.3  
Fully adjusted: calendar time, age, 
study site, presence of chronic 
conditions, sex
2,216 229 10 2,721 297 11 38.0 21.3 to 51.2
By age group 
(years)a
0–14 773 20 3 1,043 27 3 44.1 −12.3 to 72.2
15–64 1,164 69 6 1,410 126 9 46.9 25.2 to 62.3




All ages 606 201 33 698 235 34 25.7 1.5 to 43.9
Hospital
≥ 65 years 
Adjusted by study site only 267 108 40 368 191 52 −0.7 −46.8 to 30.9
Adjusted by calendar time and 
study site 267 108 40 368 191 52 3 −42.2 to 33.8
Adjusted by calendar time, age 
and study site 267 108 40 368 191 52 2.5 −43.6 to 33.8
Fully adjusted: time, age, study 
site, sex, chronic condition 
(lung, heart, renal disease, 
diabetes, cancer, obesity) and 
hospitalisation in the past year
240 95 40 316 162 51 2.0 −51.7 to 36.8
By age group 
(years)b
65–79 130 38 29 165 70 42 7.9 −67.3 to 49.3
≥ 80 115 59 51 167 102 61 2.4 −81.3 to 47.5
CI: confidence interval; VE: vaccine effectiveness at hospital level.
a Adjusted by study site, age, calendar time, presence of chronic conditions and sex.
b Adjusted by calendar time, age and study site.
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Among the 156 viruses of the 3C.2a1 clade, further 
genetic groups have emerged in 108 (69.2%) (Table 2). 
These include 34 viruses in group 1 (22%), harbouring 
the I140M substitution located in the antigenic site A 
of the haemagglutinin, in addition to changes in amino 
acid positions 171 and 121, both located in the anti-
genic site D. Eleven viruses belonged to group 2 (7%), 
carrying the T135K mutation located in the antigenic 
site A and resulting in the loss of a glycosylation site, in 
addition to the already mentioned changes in positions 
171 and 121. Twenty-eight viruses belonged to genetic 
group 3 (18%), carrying the K92R and H311Q substitu-
tions located in the antigenic sites E and C, respec-
tively, in addition to changes in positions 171 and 121. 
Finally, 35 viruses belonged to group 4 (22%), carry-
ing the R142G mutation located in the antigenic site A 
and the N171K substitution. Thirty-one viruses (67%) 
belonging to the 3C.2a clade (A/HongKong/4801/2014) 
carried the substitutions N121K and S144K, the latter 
located in the antigenic site position A.
Adjusted IVE against influenza A(H3N2) across all age 
groups was 38.0% (95% CI: 21.3 to 51.2). It was 44.1% 
(95% CI: −12.3 to 72.2), 46.9% (95% CI: 25.2 to 62.3) 
and 23.4% (95% CI: −15.4 to 49.1) in 0–14, 15–64 
and ≥ 65 year-olds, respectively. The IVE in the target 
group for vaccination was 25.7% (95% CI: 1.5 to 43.9) 
(Table 3).
Influenza vaccine effectiveness at hospital 
level
In the hospital study, we included 267 cases of influ-
enza A(H3N2) and 368 negative controls.
The 2016/17 seasonal influenza vaccine coverage was 
40.4% among influenza A(H3N2) cases and 51.9% 
among controls. A higher proportion of controls were 
vaccinated with inactivated split-virion vaccine group 
(20.6% vs 12.3%). A higher proportion of controls had 
been hospitalised for chronic conditions in the past 
twelve months (43.7% vs 26.7%) (Table 1).
Adjusted IVE against influenza A(H3N2) among those 
aged 65 years and older was 2.5% (95% CI: −43.6 to 
33.8), it was 7.9% (95% CI: −67.3 to 49.3) among those 
aged 65 to 79 years and 2.4% (95% CI: −81.3 to 47.5) 
among those aged 80 years and older (Table 3).
Discussion
In primary care, early estimates suggest moderate IVE 
against influenza A(H3N2) among 0–64-year-olds and 
low IVE in the target group for influenza vaccination. 
Among those aged 65 years and older, IVE was low at 
both primary care and hospital level, however preci-
sion was low.
Viruses of the 3C.2a1 clade (A/Bolzano/7/2016) pre-
dominated in the study sites participating in the 
laboratory protocol. Compared to the vaccine virus 
A/HongKong/4801/2014, they had the N171K substi-
tution and in addition, most of them had the N121K 
substitution. This clade appears to be antigenically 
similar to the A(H3N2) vaccine component. However, 
our sequencing results suggest that this cluster is con-
tinuing to evolve: 70% of sequenced viruses had fur-
ther mutations, forming clusters defined by new HA1 
amino acid substitutions in antigenic sites, including 
antigenic site A. We did not measure IVE against A/
Bolzano/7/2016 viruses, as estimates were not robust 
because of the small sample size.
The 2016/17 early primary care IVE estimate among 
all ages was 38% (95% CI: 21.3 to 51.2), similar to the 
early estimates from the Canadian Sentinel Practitioner 
Surveillance [10] and comparable to early estimates 
against influenza A(H3N2) in previous seasons: 43% 
(95% CI: -0.4 to 67.7) in 2011/12 and 41.9% (95% CI: 
−67.1 to 79.8) in 2012/13 [11,12]. This season, we 
reached better precision thanks to a larger sample size.
The IVE estimates among those aged 65 years and 
older and target groups for vaccination were low and, 
despite low precision, reinforce the risk assessment 
from the European Centre for Disease Prevention and 
Control (ECDC), which suggests to consider administer-
ing antiviral drugs to populations vulnerable to severe 
influenza irrespective of vaccination status, in line with 
national and international recommendations [1].
These early results are included in the Global Influenza 
Vaccine Effectiveness (GIVE) report to contribute to 
the World Health Organization consultation and infor-
mation meeting on the composition of influenza virus 
vaccines for use in the 2017/18 northern hemisphere 
influenza season [13].
Conclusion
The early season estimates presented here corroborate 
the suboptimal performance of inactivated influenza 
vaccine against influenza A(H3N2) that the I-MOVE 
team and others have reported in the previous post-
2009 pandemic seasons [14,15].
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